Alnylam Reports Publication Of Phase 1 Study Results For Zilebesiran In The New England Journal Of Medicine
Portfolio Pulse from Benzinga Newsdesk
Alnylam Pharmaceuticals has reported the publication of Phase 1 study results for Zilebesiran in the New England Journal of Medicine. The data showed that Zilebesiran was associated with dose-dependent reductions in serum AGT, achieving tonic blood pressure control with consistent and durable blood pressure reduction throughout a 24-hour period, sustained up to six months after single doses of ≥200 mg.
July 19, 2023 | 9:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The publication of positive Phase 1 study results for Alnylam's Zilebesiran could potentially boost investor confidence in the company's product pipeline.
Positive clinical trial results often lead to increased investor confidence as they indicate potential future revenue streams from the successful commercialization of the drug. In this case, the Phase 1 results for Zilebesiran show promise in controlling blood pressure, which could lead to increased demand for the drug if it is approved for commercial use.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100